| Literature DB >> 34893897 |
Jill E Lavigne1, Aleah Groman1, Michelle Price2.
Abstract
Entities:
Mesh:
Year: 2022 PMID: 34893897 PMCID: PMC9383086 DOI: 10.1093/pm/pnab340
Source DB: PubMed Journal: Pain Med ISSN: 1526-2375 Impact factor: 3.637
Curricular Elements of Sickle Cell Disease Pain Management and Implicit Bias Universal Precautions, PharmD Third Pre-Professional Year, 2020–2021
| Weeks | Course | Hours | Topic and Classroom Activities |
|---|---|---|---|
| September 7 | Population Based Healthcare | 2 | Implicit Bias and Sickle Cell Disease [ Case: NIH COPE Sharee Sickle Cell Anemia Pain Management Case [ Case: Boston Medical Center ED Sickle Cell Anemia Pain Crises, Implicit Bias and Systems Improvement [ National Academies. (2020) Addressing Sickle Cell Disease: A National Blueprint for Action |
| September 21 | Advanced Pharmacology and Therapeutics III | 2 | Opioids and Morphine Dose Equivalents (not specific to sickle cell disease) |
| January 26 to February 9 | Practice Management | 9 | Managing Implicit Bias: Self and Practice
Harvard Implicit Bias Assessment: Race Capstone Case: Devon (Workshop) Pain Crisis Pharmacotherapy Plan Quality Improvement Plan: Preventing Provider Implicit Bias Affecting Devon’s [ |
| April 24 | Advanced Pharmacology and Therapeutics IV | 2 | Sickle Cell Anemia Therapeutics |
Learning outcomes of hyflex classroom students randomized to Zoom or classroom attendance
| Instructional Element | Assessment Item | Learning Outcomes | |
|---|---|---|---|
| In-Class (A) mean (SD) N = 24 | Via Zoom (B) mean (SD) N = 27 | ||
| Harvard implicit bias self-assessment: race | |||
| Recognition of own potential bias | 15 (62.5%) | 21 (77.8%) | |
| Word count, mean (SD) | 164.8 (70.5) | 145.7 (78.9) | |
| Devon case: Pharmacotherapy recommendations | |||
| Long-acting opioid | 19 (79.2%) | 16 (59.2%) | |
| Short-acting opioid | 20 (83.3%) | 19 (70.4%) | |
| Hydroxyurea | 8 (33.3%) | 13 (48.1%) | |
| Other analgesic | 9 (37.5%) | 13 (48.1%) | |
| Stool softener | 0 (0%) | 4 (14.8%) | |
| Comorbid condition treatment | 6 (25.0%) | 11 (40.7%) | |
| Naloxone | 3 (12.5%) | 4 (14.8%) | |
| Non-pharmacologic pain management | 11 (45.85) | 13 (48.1%) | |
| Quality improvement plan to prevent provider implicit bias from affecting Devon’s care | |||
| IHI QI Essentials Toolkit Methods Applied, mean (SD) | 3.0 (1.8) | 2.4 (1.9) | |
| Word count, mean (SD) | 241.5 (141.4) | 202.4 (181.4) | |